IL113280A - A preparation for the treatment of self-immunization diseases with the help of interferon of one type - Google Patents

A preparation for the treatment of self-immunization diseases with the help of interferon of one type

Info

Publication number: IL113280A
Authority: IL; Israel
Prior art keywords: interferon; ifn; composition; fed; disease
Prior art date: 1994-04-12

Application number

IL11328095A

Other languages

English (en)

Hebrew (he)

Other versions

IL113280A0 (en

Inventor

Staley Armstrong Brod

Original Assignee

Res Dev Foundation

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-04-12

Filing date

1995-04-06

Publication date

2004-12-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26920717&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL113280(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1995-04-06 Application filed by Res Dev Foundation filed Critical Res Dev Foundation

1995-07-31 Publication of IL113280A0 publication Critical patent/IL113280A0/xx

2004-12-15 Publication of IL113280A publication Critical patent/IL113280A/en

Links

102000014150 Interferons Human genes 0.000 title claims abstract description 72
108010050904 Interferons Proteins 0.000 title claims abstract description 72
208000023275 Autoimmune disease Diseases 0.000 title claims abstract description 34
239000000203 mixture Substances 0.000 title claims description 44
229940047124 interferons Drugs 0.000 title description 15
229940079322 interferon Drugs 0.000 claims abstract description 57
206010061218 Inflammation Diseases 0.000 claims abstract description 31
230000004054 inflammatory process Effects 0.000 claims abstract description 31
241001529936 Murinae Species 0.000 claims description 21
230000002757 inflammatory effect Effects 0.000 claims description 21
201000006417 multiple sclerosis Diseases 0.000 claims description 19
230000003247 decreasing effect Effects 0.000 claims description 18
230000002401 inhibitory effect Effects 0.000 claims description 12
206010039073 rheumatoid arthritis Diseases 0.000 claims description 6
230000001684 chronic effect Effects 0.000 claims description 5
201000004681 Psoriasis Diseases 0.000 claims description 4
206010012601 diabetes mellitus Diseases 0.000 claims description 3
208000011580 syndromic disease Diseases 0.000 claims description 3
210000000056 organ Anatomy 0.000 claims description 2
208000000813 polyradiculoneuropathy Diseases 0.000 claims 2
241001465754 Metazoa Species 0.000 abstract description 80
238000000034 method Methods 0.000 abstract description 11
241000700159 Rattus Species 0.000 description 72
101000959820 Homo sapiens Interferon alpha-1/13 Proteins 0.000 description 53
102100040019 Interferon alpha-1/13 Human genes 0.000 description 53
201000010099 disease Diseases 0.000 description 48
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 48
210000001165 lymph node Anatomy 0.000 description 33
238000002649 immunization Methods 0.000 description 32
230000003053 immunization Effects 0.000 description 30
208000037187 Autoimmune Experimental Neuritis Diseases 0.000 description 29
210000004027 cell Anatomy 0.000 description 28
208000033068 episodic angioedema with eosinophilia Diseases 0.000 description 26
230000007423 decrease Effects 0.000 description 25
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 25
239000002953 phosphate buffered saline Substances 0.000 description 25
108010062580 Concanavalin A Proteins 0.000 description 23
102000047918 Myelin Basic Human genes 0.000 description 23
KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 22
102000004127 Cytokines Human genes 0.000 description 21
108090000695 Cytokines Proteins 0.000 description 21
101710107068 Myelin basic protein Proteins 0.000 description 21
239000000427 antigen Substances 0.000 description 21
108091007433 antigens Proteins 0.000 description 21
102000036639 antigens Human genes 0.000 description 21
230000000694 effects Effects 0.000 description 21
238000004519 manufacturing process Methods 0.000 description 20
230000001154 acute effect Effects 0.000 description 18
238000007920 subcutaneous administration Methods 0.000 description 18
210000001744 T-lymphocyte Anatomy 0.000 description 17
230000035755 proliferation Effects 0.000 description 17
210000000952 spleen Anatomy 0.000 description 17
238000011694 lewis rat Methods 0.000 description 16
238000011282 treatment Methods 0.000 description 15
210000000278 spinal cord Anatomy 0.000 description 14
210000004989 spleen cell Anatomy 0.000 description 14
230000002829 reductive effect Effects 0.000 description 13
102000006386 Myelin Proteins Human genes 0.000 description 12
108010083674 Myelin Proteins Proteins 0.000 description 12
238000000338 in vitro Methods 0.000 description 12
102100037850 Interferon gamma Human genes 0.000 description 11
108010074328 Interferon-gamma Proteins 0.000 description 11
230000001186 cumulative effect Effects 0.000 description 11
210000005012 myelin Anatomy 0.000 description 11
239000006228 supernatant Substances 0.000 description 10
208000016192 Demyelinating disease Diseases 0.000 description 9
206010012305 Demyelination Diseases 0.000 description 9
241000699670 Mus sp. Species 0.000 description 9
238000002474 experimental method Methods 0.000 description 9
208000027905 limb weakness Diseases 0.000 description 9
231100000861 limb weakness Toxicity 0.000 description 9
210000002540 macrophage Anatomy 0.000 description 9
238000002360 preparation method Methods 0.000 description 9
230000004044 response Effects 0.000 description 9
230000000638 stimulation Effects 0.000 description 9
WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 8
210000003141 lower extremity Anatomy 0.000 description 8
108091003079 Bovine Serum Albumin Proteins 0.000 description 7
238000003365 immunocytochemistry Methods 0.000 description 7
230000028327 secretion Effects 0.000 description 7
210000001519 tissue Anatomy 0.000 description 7
201000008827 tuberculosis Diseases 0.000 description 7
108010047761 Interferon-alpha Proteins 0.000 description 6
102000006992 Interferon-alpha Human genes 0.000 description 6
210000004969 inflammatory cell Anatomy 0.000 description 6
230000005764 inhibitory process Effects 0.000 description 6
239000003226 mitogen Substances 0.000 description 6
238000011084 recovery Methods 0.000 description 6
230000001629 suppression Effects 0.000 description 6
108090000467 Interferon-beta Proteins 0.000 description 5
206010033892 Paraplegia Diseases 0.000 description 5
238000004458 analytical method Methods 0.000 description 5
210000004837 gut-associated lymphoid tissue Anatomy 0.000 description 5
230000002519 immonomodulatory effect Effects 0.000 description 5
108700042626 macrophage-derived immunosuppressor factor Proteins 0.000 description 5
210000000578 peripheral nerve Anatomy 0.000 description 5
102000013415 peroxidase activity proteins Human genes 0.000 description 5
108040007629 peroxidase activity proteins Proteins 0.000 description 5
230000009696 proliferative response Effects 0.000 description 5
210000002966 serum Anatomy 0.000 description 5
108010041956 soluble immune response suppressor Proteins 0.000 description 5
208000024891 symptom Diseases 0.000 description 5
208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 4
241000700199 Cavia porcellus Species 0.000 description 4
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
102000002227 Interferon Type I Human genes 0.000 description 4
108010014726 Interferon Type I Proteins 0.000 description 4
108010002350 Interleukin-2 Proteins 0.000 description 4
102000000588 Interleukin-2 Human genes 0.000 description 4
238000000692 Student's t-test Methods 0.000 description 4
238000002835 absorbance Methods 0.000 description 4
239000002671 adjuvant Substances 0.000 description 4
239000006285 cell suspension Substances 0.000 description 4
210000003169 central nervous system Anatomy 0.000 description 4
230000016396 cytokine production Effects 0.000 description 4
208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 4
239000012894 fetal calf serum Substances 0.000 description 4
230000001900 immune effect Effects 0.000 description 4
239000000367 immunologic factor Substances 0.000 description 4
238000001727 in vivo Methods 0.000 description 4
230000001965 increasing effect Effects 0.000 description 4
239000007788 liquid Substances 0.000 description 4
210000004698 lymphocyte Anatomy 0.000 description 4
230000001404 mediated effect Effects 0.000 description 4
210000005036 nerve Anatomy 0.000 description 4
210000003300 oropharynx Anatomy 0.000 description 4
239000012188 paraffin wax Substances 0.000 description 4
230000001575 pathological effect Effects 0.000 description 4
239000008188 pellet Substances 0.000 description 4
238000012809 post-inoculation Methods 0.000 description 4
230000002516 postimmunization Effects 0.000 description 4
108090000765 processed proteins & peptides Proteins 0.000 description 4
235000018102 proteins Nutrition 0.000 description 4
102000004169 proteins and genes Human genes 0.000 description 4
108090000623 proteins and genes Proteins 0.000 description 4
238000011160 research Methods 0.000 description 4
DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 4
239000007790 solid phase Substances 0.000 description 4
241000894007 species Species 0.000 description 4
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
229920002554 vinyl polymer Polymers 0.000 description 4
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 4
206010003591 Ataxia Diseases 0.000 description 3
241000283690 Bos taurus Species 0.000 description 3
206010057645 Chronic Inflammatory Demyelinating Polyradiculoneuropathy Diseases 0.000 description 3
208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 3
238000002965 ELISA Methods 0.000 description 3
238000012286 ELISA Assay Methods 0.000 description 3
241000283073 Equus caballus Species 0.000 description 3
102100026720 Interferon beta Human genes 0.000 description 3
102000003996 Interferon-beta Human genes 0.000 description 3
108010063738 Interleukins Proteins 0.000 description 3
102000015696 Interleukins Human genes 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
241000699666 Mus <mouse, genus> Species 0.000 description 3
241000186359 Mycobacterium Species 0.000 description 3
206010033885 Paraparesis Diseases 0.000 description 3
238000011803 SJL/J (JAX™ mice strain) Methods 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
101001018322 Sus scrofa Myelin basic protein Proteins 0.000 description 3
230000004913 activation Effects 0.000 description 3
230000001363 autoimmune Effects 0.000 description 3
230000008512 biological response Effects 0.000 description 3
229940098773 bovine serum albumin Drugs 0.000 description 3
230000003915 cell function Effects 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
230000003111 delayed effect Effects 0.000 description 3
239000000839 emulsion Substances 0.000 description 3
210000001035 gastrointestinal tract Anatomy 0.000 description 3
210000000987 immune system Anatomy 0.000 description 3
230000004957 immunoregulator effect Effects 0.000 description 3
230000006698 induction Effects 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
238000011081 inoculation Methods 0.000 description 3
PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 3
PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 3
210000000265 leukocyte Anatomy 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
230000004048 modification Effects 0.000 description 3
238000012986 modification Methods 0.000 description 3
230000008569 process Effects 0.000 description 3
238000010186 staining Methods 0.000 description 3
238000007619 statistical method Methods 0.000 description 3
239000000126 substance Substances 0.000 description 3
210000000538 tail Anatomy 0.000 description 3
230000003612 virological effect Effects 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
241000700198 Cavia Species 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
102000000503 Collagen Type II Human genes 0.000 description 2
108010041390 Collagen Type II Proteins 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
208000009386 Experimental Arthritis Diseases 0.000 description 2
208000035895 Guillain-Barré syndrome Diseases 0.000 description 2
241000282412 Homo Species 0.000 description 2
101001054334 Homo sapiens Interferon beta Proteins 0.000 description 2
206010062016 Immunosuppression Diseases 0.000 description 2
LUWJPTVQOMUZLW-UHFFFAOYSA-N Luxol fast blue MBS Chemical compound [Cu++].Cc1ccccc1N\C(N)=N\c1ccccc1C.Cc1ccccc1N\C(N)=N\c1ccccc1C.OS(=O)(=O)c1cccc2c3nc(nc4nc([n-]c5[n-]c(nc6nc(n3)c3ccccc63)c3c(cccc53)S(O)(=O)=O)c3ccccc43)c12 LUWJPTVQOMUZLW-UHFFFAOYSA-N 0.000 description 2
102000043131 MHC class II family Human genes 0.000 description 2
108091054438 MHC class II family Proteins 0.000 description 2
206010049567 Miller Fisher syndrome Diseases 0.000 description 2
108700028031 Myelin Basic Proteins 0.000 description 2
229930182555 Penicillin Natural products 0.000 description 2
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 description 2
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
206010070834 Sensitisation Diseases 0.000 description 2
230000005856 abnormality Effects 0.000 description 2
230000008901 benefit Effects 0.000 description 2
RIIWUGSYXOBDMC-UHFFFAOYSA-N benzene-1,2-diamine;hydron;dichloride Chemical compound Cl.Cl.NC1=CC=CC=C1N RIIWUGSYXOBDMC-UHFFFAOYSA-N 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000000601 blood cell Anatomy 0.000 description 2
230000037396 body weight Effects 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
239000000872 buffer Substances 0.000 description 2
230000006037 cell lysis Effects 0.000 description 2
230000004663 cell proliferation Effects 0.000 description 2
230000002950 deficient Effects 0.000 description 2
230000001934 delay Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
239000012895 dilution Substances 0.000 description 2
238000010790 dilution Methods 0.000 description 2
238000012377 drug delivery Methods 0.000 description 2
YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
210000003194 forelimb Anatomy 0.000 description 2
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
229960002163 hydrogen peroxide Drugs 0.000 description 2
238000007654 immersion Methods 0.000 description 2
230000028993 immune response Effects 0.000 description 2
230000016784 immunoglobulin production Effects 0.000 description 2
230000001506 immunosuppresive effect Effects 0.000 description 2
238000011065 in-situ storage Methods 0.000 description 2
229940047122 interleukins Drugs 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
239000000463 material Substances 0.000 description 2
238000000386 microscopy Methods 0.000 description 2
239000003607 modifier Substances 0.000 description 2
230000000897 modulatory effect Effects 0.000 description 2
230000007971 neurological deficit Effects 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
230000008506 pathogenesis Effects 0.000 description 2
229940049954 penicillin Drugs 0.000 description 2
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
210000001986 peyer's patch Anatomy 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
229920000136 polysorbate Polymers 0.000 description 2
230000009467 reduction Effects 0.000 description 2
230000008313 sensitization Effects 0.000 description 2
229940054269 sodium pyruvate Drugs 0.000 description 2
239000000243 solution Substances 0.000 description 2
229960005322 streptomycin Drugs 0.000 description 2
239000000758 substrate Substances 0.000 description 2
239000002512 suppressor factor Substances 0.000 description 2
238000012353 t test Methods 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
230000004580 weight loss Effects 0.000 description 2
OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
208000030090 Acute Disease Diseases 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
238000012935 Averaging Methods 0.000 description 1
210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 1
210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
229910021592 Copper(II) chloride Inorganic materials 0.000 description 1
244000304337 Cuminum cyminum Species 0.000 description 1
206010012438 Dermatitis atopic Diseases 0.000 description 1
239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
241000283086 Equidae Species 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
206010017577 Gait disturbance Diseases 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
206010021639 Incontinence Diseases 0.000 description 1
108090001005 Interleukin-6 Proteins 0.000 description 1
102000004889 Interleukin-6 Human genes 0.000 description 1
102000003960 Ligases Human genes 0.000 description 1
108090000364 Ligases Proteins 0.000 description 1
102000043129 MHC class I family Human genes 0.000 description 1
108091054437 MHC class I family Proteins 0.000 description 1
TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
235000021360 Myristic acid Nutrition 0.000 description 1
206010060860 Neurological symptom Diseases 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
229930040373 Paraformaldehyde Natural products 0.000 description 1
208000030852 Parasitic disease Diseases 0.000 description 1
206010057249 Phagocytosis Diseases 0.000 description 1
101000999323 Rattus norvegicus Cobalamin binding intrinsic factor Proteins 0.000 description 1
206010038687 Respiratory distress Diseases 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
241000282887 Suidae Species 0.000 description 1
230000006052 T cell proliferation Effects 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
241000700605 Viruses Species 0.000 description 1
SIIZPVYVXNXXQG-KGXOGWRBSA-N [(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-4-[[(3s,4r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-3-hydroxyoxolan-2-yl]methyl [(2r,4r,5r)-2-(6-aminopurin-9-yl)-4-hydroxy-5-(phosphonooxymethyl)oxolan-3-yl] hydrogen phosphate Polymers C1=NC2=C(N)N=CN=C2N1[C@@H]1O[C@H](COP(O)(=O)OC2[C@@H](O[C@H](COP(O)(O)=O)[C@H]2O)N2C3=NC=NC(N)=C3N=C2)[C@@H](O)[C@H]1OP(O)(=O)OCC([C@@H](O)[C@H]1O)OC1N1C(N=CN=C2N)=C2N=C1 SIIZPVYVXNXXQG-KGXOGWRBSA-N 0.000 description 1
SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000009471 action Effects 0.000 description 1
231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
230000004075 alteration Effects 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
229910052921 ammonium sulfate Inorganic materials 0.000 description 1
235000011130 ammonium sulphate Nutrition 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
230000001028 anti-proliverative effect Effects 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
201000008937 atopic dermatitis Diseases 0.000 description 1
230000003190 augmentative effect Effects 0.000 description 1
210000003050 axon Anatomy 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
208000025698 brain inflammatory disease Diseases 0.000 description 1
244000309466 calf Species 0.000 description 1
238000001516 cell proliferation assay Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
230000003210 demyelinating effect Effects 0.000 description 1
210000004443 dendritic cell Anatomy 0.000 description 1
238000011161 development Methods 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000000378 dietary effect Effects 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000003814 drug Substances 0.000 description 1
238000010828 elution Methods 0.000 description 1
206010014599 encephalitis Diseases 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000037406 food intake Effects 0.000 description 1
239000012634 fragment Substances 0.000 description 1
230000009454 functional inhibition Effects 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
238000003304 gavage Methods 0.000 description 1
239000011544 gradient gel Substances 0.000 description 1
210000003714 granulocyte Anatomy 0.000 description 1
244000144993 groups of animals Species 0.000 description 1
210000002443 helper t lymphocyte Anatomy 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
230000008348 humoral response Effects 0.000 description 1
230000005934 immune activation Effects 0.000 description 1
210000002865 immune cell Anatomy 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
230000003259 immunoinhibitory effect Effects 0.000 description 1
230000007233 immunological mechanism Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
239000002054 inoculum Substances 0.000 description 1
229960001388 interferon-beta Drugs 0.000 description 1
230000031261 interleukin-10 production Effects 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
-1 myristic acid palmityl ester Chemical class 0.000 description 1
OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
201000001119 neuropathy Diseases 0.000 description 1
230000007823 neuropathy Effects 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
239000012285 osmium tetroxide Substances 0.000 description 1
229910000489 osmium tetroxide Inorganic materials 0.000 description 1
230000000242 pagocytic effect Effects 0.000 description 1
229920002866 paraformaldehyde Polymers 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
229960001412 pentobarbital Drugs 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
230000008782 phagocytosis Effects 0.000 description 1
239000000902 placebo Substances 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
230000013777 protein digestion Effects 0.000 description 1
230000012121 regulation of immune response Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000019254 respiratory burst Effects 0.000 description 1
230000004043 responsiveness Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
210000004116 schwann cell Anatomy 0.000 description 1
239000002002 slurry Substances 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
210000000273 spinal nerve root Anatomy 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
238000012360 testing method Methods 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000020192 tolerance induction in gut-associated lymphoid tissue Effects 0.000 description 1
229950003937 tolonium Drugs 0.000 description 1
HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 1
231100000041 toxicology testing Toxicity 0.000 description 1
238000000870 ultraviolet spectroscopy Methods 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Immunology (AREA)
Chemical Kinetics & Catalysis (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Rheumatology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Biomedical Technology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)

IL11328095A 1994-04-12 1995-04-06 A preparation for the treatment of self-immunization diseases with the help of interferon of one type IL113280A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US22663194A	1994-04-12	1994-04-12
US40827195A	1995-03-24	1995-03-24

Publications (2)

Publication Number	Publication Date
IL113280A0 IL113280A0 (en)	1995-07-31
IL113280A true IL113280A (en)	2004-12-15

Family

ID=26920717

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL11328095A IL113280A (en)	1994-04-12	1995-04-06	A preparation for the treatment of self-immunization diseases with the help of interferon of one type

Country Status (13)

Country	Link
EP (1)	EP0752884B1 (de)
JP (1)	JPH09511989A (de)
KR (1)	KR100424212B1 (de)
AT (1)	ATE271879T1 (de)
AU (1)	AU695260B2 (de)
CA (1)	CA2187550A1 (de)
DE (1)	DE69533311T2 (de)
DK (1)	DK0752884T3 (de)
ES (1)	ES2224124T3 (de)
IL (1)	IL113280A (de)
NZ (1)	NZ284276A (de)
SA (1)	SA95160081B1 (de)
WO (1)	WO1995027502A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5906816A (en) *	1995-03-16	1999-05-25	University Of Florida	Method for treatment of autoimmune diseases
US6372206B1 (en) *	1989-03-02	2002-04-16	University Of Florida	Orally-administered interferon-TAU compositions and methods
CA2253971A1 (en)	1996-05-09	1997-11-13	Pharma Pacific Pty.Ltd.	Use of high dose interferon by oralmucosal contact to treat viral infections and neoplastic conditions
AUPN976596A0 (en) *	1996-05-09	1996-05-30	Pharma Pacific Pty Ltd	Stimulation of host defence mechanisms
SK2942002A3 (en) *	1999-08-27	2002-08-06	Maxygen Aps	A conjugate exhibiting interferon beta, a nucleotide sequence, an expressing vector, a host cell containing such a nucleotide sequence, method for the preparation thereof, pharmaceutical composition containing the same and its use
US7144574B2 (en)	1999-08-27	2006-12-05	Maxygen Aps	Interferon β variants and conjugates
US6531122B1 (en)	1999-08-27	2003-03-11	Maxygen Aps	Interferon-β variants and conjugates
US7431921B2 (en)	1999-08-27	2008-10-07	Maxygen Aps	Interferon beta-like molecules
BR0314548A (pt) *	2002-09-27	2005-08-09	Biogen Idec Inc	Terapias para polineuropatia de desmielinação inflamatória crÈnica empregando-se interferon-beta
EP1582216A4 (de)	2002-12-26	2010-04-21	Asubio Pharma Co Ltd	Heilmittel für pemphigoid
US20210228687A1 (en) *	2018-06-01	2021-07-29	Ilc Therapeutics Ltd	Compositions and methods relating to the treatment of diseases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA878295B (en) *	1986-11-06	1988-05-03	Amarillo Cell Culture Co. Inc.	Treatment of immuno-resistant disease

1995
- 1995-04-06 IL IL11328095A patent/IL113280A/en not_active IP Right Cessation
- 1995-04-11 NZ NZ284276A patent/NZ284276A/en not_active IP Right Cessation
- 1995-04-11 CA CA002187550A patent/CA2187550A1/en not_active Abandoned
- 1995-04-11 ES ES95916293T patent/ES2224124T3/es not_active Expired - Lifetime
- 1995-04-11 DE DE69533311T patent/DE69533311T2/de not_active Expired - Fee Related
- 1995-04-11 KR KR1019960705724A patent/KR100424212B1/ko not_active Expired - Fee Related
- 1995-04-11 WO PCT/US1995/004420 patent/WO1995027502A1/en not_active Ceased
- 1995-04-11 EP EP95916293A patent/EP0752884B1/de not_active Expired - Lifetime
- 1995-04-11 AU AU22839/95A patent/AU695260B2/en not_active Ceased
- 1995-04-11 JP JP7526504A patent/JPH09511989A/ja active Pending
- 1995-04-11 AT AT95916293T patent/ATE271879T1/de not_active IP Right Cessation
- 1995-04-11 DK DK95916293T patent/DK0752884T3/da active
- 1995-06-28 SA SA95160081A patent/SA95160081B1/ar unknown

Also Published As

Publication number	Publication date
EP0752884B1 (de)	2004-07-28
JPH09511989A (ja)	1997-12-02
DE69533311D1 (de)	2004-09-02
DE69533311T2 (de)	2005-07-21
AU2283995A (en)	1995-10-30
EP0752884A4 (de)	1999-04-07
ES2224124T3 (es)	2005-03-01
EP0752884A1 (de)	1997-01-15
SA95160081B1 (ar)	2005-09-19
IL113280A0 (en)	1995-07-31
ATE271879T1 (de)	2004-08-15
DK0752884T3 (da)	2004-11-22
AU695260B2 (en)	1998-08-13
WO1995027502A1 (en)	1995-10-19
CA2187550A1 (en)	1995-10-19
KR100424212B1 (ko)	2004-07-21
NZ284276A (en)	2000-07-28
KR970702063A (ko)	1997-05-13

Legal Events

Date	Code	Title
2005-05-17	FF	Patent granted
2005-06-19	KB	Patent renewed
2010-05-17	MM9K	Patent not in force due to non-payment of renewal fees

Publication	Publication Date	Title
AU689236B2 (en)	1998-03-26	Use of IL-12 and IL-12 antagonists in the treatment of autoimmune diseases
Karussis et al.	1993	Treatment of chronic-relapsing experimental autoimmune encephalomyelitis with the synthetic immunomodulator linomide (quinoline-3-carboxamide).
TW474817B (en)	2002-02-01	Kits for treatment of multiple sclerosis using consensus interferon
Brod et al.	1994	Suppression of relapsing experimental autoimmune encephalomyelitis in the SJL/J mouse by oral administration of type I interferons
JP2000507917A (ja)	2000-06-27	持続的低用量サイトカイン注入治療
US8231874B2 (en)	2012-07-31	Use of IL-12 and IL-12 antagonists in the treatment of autoimmune diseases
Brod et al.	1996	Oral administration of IFN-α is superior to subcutaneous administration of IFN-α in the suppression of chronic relapsing experimental autoimmune encephalomyelitis
EP0752884B1 (de)	2004-07-28	Verfahren zur behandlung von autoimmunerkrankungen mittels typ-1-interferonen
Brod et al.	1995	Modification of acute experimental autoimmune encephalomyelitis in the Lewis rat by oral administration of type 1 interferons
US20090214473A1 (en)	2009-08-27	Combination chaperonin 10 and beta-interferon therapy for multiple sclerosis
RU2166959C2 (ru)	2001-05-20	Способ лечения аутоиммунных заболеваний с использованием интерферонов типа i
CA1290687C (en)	1991-10-15	Process for treatment of allergies
Vriesendorp et al.	1996	Oral administration of type I interferon modulates the course of experimental allergic neuritis
US7790153B2 (en)	2010-09-07	Method of treating rheumatoid arthritis using orally administered type one interferons
Okada et al.	1998	Kinetics of intraocular cytokines in the suppression of experimental autoimmune uveoretinitis by type I IFN.
JP2001522811A (ja)	2001-11-20	インターフェロン免疫療法
US20030017135A1 (en)	2003-01-23	Pharmaceutical compositions comprising vitamin B12 and interferon for treating multiple sclerosis
Brod	1997	Effects of Oral Administration of Type I Interferons on Experimental Autoimmune Encephalomyelitis
JPH08500823A (ja)	1996-01-30	レトロウィルス関連神経疾患のバイスタンダー抑制
Siegfried et al.	1994	Melanin can deplete immunosuppressive substances from the aqueous humor
MXPA00001207A (en)	2001-03-05	Methods for treatment of patients afflicted wih multiple sclerosis using consensus interferon